Autoimmune Thyroid Disease in Rheumatoid Arthritis: A Global Perspective

Table 1

Characteristics of 800 patients with RA.

Characteristic
Age (years)	51.92 (12.19)^a
Age at onset (years)	39.58 (12.35)^a
RA duration (years)	10 (14)^b
Educational level (years)	11 (9)^b
Body mass index	24 (5.8)^b
DAS28	3.63 (2.12)^b
HAQ	1.05 (1.31)^b
Sociodemographic	n/N (%)
Female	650/800 (81.3)
Low educational level	264/692 (38.2)
Low socioeconomic status	234/780 (30.0)
Current smoking	85/768 (11.1)
Household duties	254/684 (37.1)
Clinical aspects
Type 2 diabetes	32/737 (4.3)
Dyslipidemia	184/752 (24.5)
Hypertension	208/752 (27.7)
Thrombosis	39/738 (5.3)
Cardiovascular disease	173/781 (22.2)
Body mass index > 25	394/681 (57.9)
Abdominal obesity	460/683 (67.4)
Aspirin use	105/653 (16.1)
Abnormal cholesterol	179/333 (53.8)
RA characteristics
Disease duration > 10 years	393/703 (55.9)
Erosions	349/451 (77.4)
EAMs with CVD	402/793 (50.7)
Rheumatoid factor+	573/717 (79.9)
Anti CCP+	312/384 (81.3)
Methotrexate	702/794 (88.4)
DMARD (any)	783/794 (98.6)
Antimalarials	633/793 (79.8)
Steroids	705/793 (88.9)
Biological Agents	276/794 (34.8)
Autoimmunity
Autoimmune thyroid disease	78/800 (9.8)
Systemic lupus erythematosus	11/709 (1.6)
Sjögren’s syndrome	24/800 (3.0)
Polyautoimmunity	113/800 (14.1)
Polyautoimmunity^c	35/800 (4.8)
MAS	17/714 (2.4)
Familial autoimmunity FDR	104/800 (13.0)
ANAs+	310/448 (69.2)
Anti Ro+	43/287 (15.0)
Anti La+	20/285 (7.0)
TPOAb+	51/135 (37.8)
TgAb+	26/125 (20.8)

ANAs: antinuclear antibodies; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; CVD: cardiovascular disease; DAS28: disease activity score; DMARD: disease modifying antirheumatic drugs; EAM: extra-articular manifestations; ESR: erythrocyte sedimentation rate; FDR: first degree relatives; HAQ: health assessment questionnaire; MAS: multiple autoimmune syndrome; RA: rheumatoid arthritis; TgAb: anti-thyroglobulin; TPOAb: anti-thyroperoxidase enzyme.
^a Mean (standard deviation).
^b Median (interquartile range).
^c Without taking AITD into account.